Invention Grant
- Patent Title: Engineering and delivery of therapeutic compositions of freshly isolated cells
-
Application No.: US14834932Application Date: 2015-08-25
-
Publication No.: US09669058B2Publication Date: 2017-06-06
- Inventor: Linhong Li , Madhusudan V. Peshwa
- Applicant: Maxcyte, Inc.
- Applicant Address: US MD Gaithersburg
- Assignee: Maxcyte, Inc.
- Current Assignee: Maxcyte, Inc.
- Current Assignee Address: US MD Gaithersburg
- Agency: Norton Rose Fulbright US LLP
- Main IPC: C12N15/87
- IPC: C12N15/87 ; A61K48/00 ; A61K35/17 ; A61K39/00 ; C12N5/078 ; C12N5/0783 ; A61K39/395 ; C12N13/00 ; C12N15/85 ; A61K35/12
Abstract:
The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing.
Public/Granted literature
- US20160082045A1 Engineering and Delivery of Therapeutic Compositions of Freshly Isolated Cells Public/Granted day:2016-03-24
Information query
IPC分类:
